Intravitreal Bevacizumab in Vitreous Hemorrhage and Diabetes Mellitus (Response from the Authors )

Kaynakça (1)

1. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev. 2012;12:CD007419. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with agerelated macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454-459. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015;314:2137- 2146. Alagöz C, Yıldırım Y, Kocamaz M, Baz Ö, Çiçek U, Çelik B, Demirkale Hİ, Yazıcı AT, Taşkapılı M. The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects. Turk J Ophthalmol. 2016;46:221-225.